Bone loss and gout: Latest side effects of GLP-1 drugs
Losing weight is universally challenging. So it’s no surprise that a new class of weight-loss medications has surged in popularity, especially among patients with obesity and type 2 diabetes. Nearly 20% of adults aged 50–64 now take these drugs — known as GLP-1 receptor agonists — making middle-aged adults their largest consumer group. For many, the results have been impressive. But with any fast-acting drug comes an important question: What…